DV
Dividend Vision

AMRN — Amarin Corporation plc

Amarin Corporation plc (AMRN)

Total return is -99.9% over the past 33.4 years, 3126.0 points behind SPY at 3026.1%. Its deepest 1-year drawdown was 33.3%.

Amarin Corporation plc is a pharmaceutical company that develops and commercializes therapeutics for cardiovascular disease, primarily its prescription drug Vascepa (icosapent ethyl), an omega-3 fatty acid product used to reduce triglyceride levels in patients with severe hypertriglyceridemia. The company sells its products through wholesalers and pharmacy providers in the United States, Europe, and internationally, and collaborates with Mochida Pharmaceutical on related drug development. As an operating pharmaceutical company, Amarin does not follow a set distribution schedule, and its dividend policy is not currently established.

AMRN key facts

Asset type
Stock
Asset class
Equity
Inception date
04/01/1993
Distribution frequency
None
Last close
$14.07
Market cap
$295,035,328
Average volume
52500.0
Beta
0.765
Payout ratio
0.0
Forward P/E
500.0
EPS
$-1.20